Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Madrigal Pharmaceuticals Inc
Accounts Payable
Madrigal Pharmaceuticals Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
Accounts Payable
$46m
|
CAGR 3-Years
29%
|
CAGR 5-Years
107%
|
CAGR 10-Years
31%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$833m
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$21.5B
|
CAGR 3-Years
150%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.6B
|
CAGR 3-Years
165%
|
CAGR 5-Years
110%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$5.7B
|
CAGR 3-Years
116%
|
CAGR 5-Years
68%
|
CAGR 10-Years
50%
|
|
Madrigal Pharmaceuticals Inc
Glance View
In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.
See Also
What is Madrigal Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
46m
USD
Based on the financial report for Dec 31, 2024, Madrigal Pharmaceuticals Inc's Accounts Payable amounts to 46m USD.
What is Madrigal Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
31%
Over the last year, the Accounts Payable growth was 64%. The average annual Accounts Payable growth rates for Madrigal Pharmaceuticals Inc have been 29% over the past three years , 107% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet